Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Rajat Bannerji, Jon E Arnason, Ranjana H Advani, Jennifer R Brown, John N Allan, Stephen M Ansell, Jeffrey A Barnes, Susan M O'Brien, Julio C Chávez, Johannes Duell, Andreas Rosenwald, Jennifer L Crombie, Melanie Ufkin, Jingjin Li, Min Zhu, Srikanth R Ambati, Aafia Chaudhry, Israel Lowy, Max S Topp